Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C

Liver International

Volumn 35, Issue s1, 2015, Pages 11-17

  Welch, Nicole M ^a   Jensen, Donald M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Direct acting antiviral agents; Genotype 1 HCV; Hepatitis C; Hepatitis C therapy; Pegylated interferon based therapies

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; MACROGOL DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDE; URIDINE PHOSPHATE; VIRUS PROTEIN;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; PROCEDURES;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84919683883     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12715     Document Type: Review

References (36)

1. US Department of Health and Human Services NIH. Hepatitis C. Available at https://www.niaid.nih.gov/topics/hepatitis/hepatitisc/Pages/Default.aspx. Accessed: 12 July 2014.
2. World Health Organization: Global Alert and Response. Hepatitis C. 2014. Available at http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index2.html. Accessed: 12 July 2014.
3. Strader D, Wright T, Thomas D, Seeff L. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
4. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
5. Reddy K, Nelson D, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009; 50: 402-11.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
7. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
8. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
9. Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142.e4.
10. Bronowicki JP, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior PegIFN/RBV (PR) treatment failures after retreatment with boceprevir (BOC) + PR: the PROVIDE study interim results. J Hepatol 2012; 56: S6.
11. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicenter cohort of the French Early Access Programme. J Hepatol 2013; 59: 434-41.
12. Asselah T, Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int 2014; 34(Suppl 1): 60-8.
13. Aronsohn A, Jensen D. Interferon-combination strategies for the treatment of chronic hepatitis C. Semin Liver Dis 2014; 34: 30-6.
14. Jacobson I, Dore G, Foster G, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C genotype 1 infection (QUEST-1): a phase 3 randomised, double-blind, placebo controlled trial. Lancet 2014; 384: 403-13.
15. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
16. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41.
17. Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-a-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: the CONCERTO-4 study. Hepatology Res 2014; doi: 10.1111/hepr.12375. [Epub ahead of print].
18. Summa V, Ludmerer S, McCauley J, Fandozzi C, Burlein C. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56: 4161-7.
19. Manns M, Vierling K, Bacon B, Marcellin P. High sustained viral response of MK-5172 with pegylated interferon alfa-2b and ribavirin in HCV genotype 1 treatment-naïve non-cirrhotic patients. Presented at: The 48th Annual Meeting of the European Association for the Study of the Liver. April 24-28, 2013, Amsterdam, the Netherlands.
20. Bronowicki JP, Ratziu V, Gadano A, et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol 2014; 61: 1220-7.
21. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
22. Jensen D, Asselah T, Dieterich D, Foster G, Sulkowski M. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso 1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C genotype-1 infection. Presented at: The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013. October 15 2013.
23. Dieterich D, Asselah T, Guyader D, et al. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naïve hepatitis C virus genotype 1-infected patients. Antimicrob Agents Chemother 2014; 58: 3429-36.
24. Sulkowski MS, Bourliere M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-63.
25. Jacobson IM, Asselah T, Ferenci P, et al. STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. Presented at: The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013. October 15 2013.
26. Hézode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve HCV-Genotype 1 or 4 Patients: Phase 2b COMMAND-1 SVR12 Results. Presented at: Presented at: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-11, 2012; Boston, MA.
27. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-7.
28. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8.
29. Pockros PJ, Jensen D, Tsai N, et al. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58: 514-23.
30. Wedemeyer H, Jensen D, Herring R Jr, et al. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58: 524-37.
31. Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null-responders: results from the MATTERHORN study. Presented at: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-11, 2012; Boston, MA.
32. Lok A, Gardiner D, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490-9.
33. Jensen D, Sherman K, Hezode C, et al. Daclatasvir and Asunaprevir Plus Peginterferon Alfa and Ribavirin in HCV Genotype 1 or 4 Nonresponders. IDSA abstract. October 10, 2014; Philadelphia, PA.
34. Nelson DR, Gane E, Jacobson IM, et al. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Hepatology 2011; 54: 1435A.
35. Pol S, Jablkowski M, Trenkle JD, et al. Antiviral efficacy of the NS3 protease inhibitor GS-9451, non-nucleoside NS5b inhibitor, tegobuvir, and pegylated interferon plus ribavirin in treatment-naïve genotype 1 hepatitis C infected patients. J Hepatol 2013; 58: S25-44.
36. American Association for the Study of Liver Diseases. Summary of Recommendations for Patients Who are Initiating Therapy for HCV Infection or Who Experienced Relapse after Prior PEG/RBV Therapy, by HCV Genotype. 2014. Available at http://www.hcvguidelines.org/full-report/initial-treatment-box-summary-recommendations-patients-who-are-initiating-therapy-hcv. Accessed: 6 September 2014.